Steven M. Hersch
Affiliations: | Neurology | Harvard Medical School - Massachusetts General Hospital |
Google:
"Steven Hersch"Mean distance: 16.58 (cluster 29)
Children
Sign in to add trainee| Gregory Lieberman | research assistant | 2004-2007 | Harvard Medical School - Massachusetts General Hospital |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Langbehn DR, Hersch S. (2020) Clinical Outcomes and Selection Criteria for Prodromal Huntington's Disease Trials. Movement Disorders |
| Stephen CD, Hung J, Schifitto G, et al. (2018) Electrocardiogram Abnormalities Suggest Aberrant Cardiac Conduction in Huntington's Disease. Movement Disorders Clinical Practice. 5: 306-311 |
| Rosas HD, Wilkens P, Salat DH, et al. (2018) Complex spatial and temporally defined myelin and axonal degeneration in Huntington disease. Neuroimage. Clinical. 20: 236-242 |
| Schobel SA, Palermo G, Auinger P, et al. (2017) Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology |
| Hersch SM, Schifitto G, Oakes D, et al. (2017) The CREST-E study of creatine for Huntington disease: A randomized controlled trial. Neurology |
| Quinti L, Dayalan Naidu S, Träger U, et al. (2017) KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients. Proceedings of the National Academy of Sciences of the United States of America |
| Chopra V, Quinti L, Khanna P, et al. (2016) LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease. Journal of Huntington's Disease. 5: 347-355 |
| Rosas HD, Doros G, Bhasin S, et al. (2015) A systems-level "misunderstanding": the plasma metabolome in Huntington's disease. Annals of Clinical and Translational Neurology. 2: 756-68 |
| Lu Z, Marks E, Chen J, et al. (2014) Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model. Neurobiology of Disease. 71: 34-42 |
| Rosas HD, Doros G, Gevorkian S, et al. (2014) PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology. 82: 850-7 |